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E-mail address: jean.vance@ualberta.ca (J.E. VancePathways of intracellular cholesterol trafﬁcking are poorly understood at the molecular level. Muta-
tions in Niemann-Pick C (NPC) proteins, NPC1 and NPC2, however, have led to insights into the
mechanism by which endocytosed cholesterol is exported from late endosomes/lysosomes (LE/L).
Mutations in NPC1, a multi-spanning membrane protein of LE/L, or mutations in NPC2, a soluble
luminal protein of LE/L, cause the neurodegenerative disorder NPC disease. This review focuses on
data supporting a model in which movement of cholesterol out of LE/L is mediated by the sequential
action of the two NPC proteins. We also discuss potential therapies for NPC disease, including evi-
dence that treatment of NPC-deﬁcient mice with the cholesterol-binding compound, cyclodextrin,
markedly attenuates neurodegeneration, and increases life-span, of NPC1-deﬁcient mice.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Niemann-Pick type C (NPC) disease is a fatal, autosomal reces-
sive disorder that affects approximately 1 in 150,000 live births
[1]. The majority of cases result from mutations in the NPC1 gene
(95%) while the remainder (5%) are caused by mutations in the
NPC2 gene. Loss of function of either of these proteins results in
an accumulation of cholesterol and other lipids, including sphingo-
myelin, sphingosine and gangliosides (GM2 and GM3), within the
late endosomes/lysosomes (LE/L). In mice and humans, this
impairment leads to progressive neurodegeneration, hepatosplen-
omegaly and, ultimately, premature death. Typically, clinical man-
ifestations become evident in early childhood, although age of
onset can range from the perinatal period to adulthood. Disease
progression is often more rapid when onset of symptoms occurs
in early life [2].
Cells acquire cholesterol through endogenous synthesis, as well
as through the uptake of exogenous sources of cholesterol, partic-
ularly low density lipoproteins (LDLs). LDLs are brought into the
cell via receptor-mediated endocytosis and are delivered to thechemical Societies. Published by E
sferase; ALLO, allopregnano-
central nervous system; ER,
low density lipoprotein; LE/L,
C
ersity of Alberta, Edmonton,
).LE/L, where cholesterol esters (CE) within the core of the LDL
particle are hydrolyzed by acid lipase [3]. Unesteriﬁed cholesterol
exits the LE/L, apparently through an NPC1/NPC2-dependent
mechanism, and is distributed to the plasma membrane as well
as the endoplasmic reticulum (ER). The ER serves as a cholesterol
sensor, allowing the cell to regulate cholesterol synthesis and up-
take via the sterol regulatory element-binding protein pathway
[4]. Additionally, cholesterol at the ER can be re-esteriﬁed by
acyl-CoA:cholesterol acyltransferase (ACAT) [3].
Initial studies by Pentchev et al. found that ﬁbroblasts from
NPC1-deﬁcient patients have a defect in cholesterol esteriﬁcation
despite having normal ACAT activity [5]. Staining of these cells
with ﬁlipin, which labels unesteriﬁed cholesterol, suggested that
although LDL-cholesterol is internalized and hydrolyzed normally
in these ﬁbroblasts, its movement to the ER is blunted [5]. Conse-
quently, LDL is unable to decrease cholesterol biosynthesis and
LDL-receptor activity, both of which are regulated at the ER [6].
Cytochemical techniques conﬁrmed that there is a massive storage
of cholesterol within the lysosomes of NPC-deﬁcient ﬁbroblasts
[7]. More recent studies have begun to unravel the molecular
and cell biological basis of these ﬁndings.2. NPC1 and NPC2 proteins
Positional cloning techniques have identiﬁed the human NPC1
gene (on chromosome 18q11) and its orthologs in mice, the yeast
Saccharomyces cerevisiae, the nematode Caenorhabditis elegans [8,9]lsevier B.V. All rights reserved.
Fig. 1. Potential mechanism for NPC1/NPC2-mediated cholesterol export from LE/L.
(1) NPC2 (soluble protein) binds unesteriﬁed cholesterol in the LE/L with the
iso-octyl chain in the binding pocket, an event that may be enhanced by
bis(monoacylglycero)phosphate. (2) NPC2 transfers cholesterol to the N-terminal
loop of NPC1 (a multi-pass membrane protein) which binds cholesterol with the
hydroxyl group in the binding pocket. (3) Cholesterol is exported from LE/L by an
unknown mechanism.
2732 K.B. Peake, J.E. Vance / FEBS Letters 584 (2010) 2731–2739and Drosophila [10]. Expression of NPC1 in cultured ﬁbroblasts
from patients with NPC disease abolished the lysosomal accumula-
tion of cholesterol [8]. NPC1 is an integral membrane protein that
is primarily localized to the LE/L, although this protein also appears
to cycle through the trans-Golgi network [11,12]. Human NPC1
consists of 1278 amino acids and contains 13 putative transmem-
brane domains that are separated by three luminal glycosylated
loops [8,13]. Moreover, NPC1 contains a sterol-sensing domain that
has a similar sequence to that in 3-hydroxy-3-methylglutaryl-CoA
reductase, sterol regulatory element-binding protein cleavage acti-
vating protein and Patched [8].
Through studies that were designed to characterize the lyso-
somal proteome, the gene responsible for NPC2 disease was subse-
quently identiﬁed [14]. NPC2 (previously called HE1) is a
ubiquitously expressed 151-amino acid, soluble lysosomal protein
[14]. Originally, NPC2 was identiﬁed as a cholesterol-binding pro-
tein that is a major secretory component of epididymal ﬂuid [15].
Fluorescence quenching assays showed that NPC2 can transfer
cholesterol between phospholipid vesicles. In addition, the transfer
of cholesterol from phospholipid vesicles to NPC2 is dramatically
increased by the presence of bis(monoacylglycero)phosphate (a
LE/L phospholipid that accumulates in NPC-deﬁcient cells) in
donor vesicles [16].
Homozygous mutations in either NPC1 or NPC2 result in virtu-
ally identical cellular and clinical phenotypes [17]. Likewise,
when NPC1-deﬁcient mice are crossed with Npc2 hypomorphic
mice, which retain 0–4% residual NPC2 protein, the phenotype
is indistinguishable from that of either NPC1- or NPC2-deﬁcient
mice [18], suggesting that these proteins function in tandem, or
sequentially, in the same pathway. Binding studies and crystal
structures of NPC1 and NPC2 have provided valuable insights into
the functions of these proteins. NPC2 binds cholesterol with high
afﬁnity in a process that is sensitive to modiﬁcation of the hydro-
phobic side-chain of cholesterol [15,19]. A crystal structure of bo-
vine NPC2 bound to cholesterol sulfate shows that cholesterol
binds in a deep hydrophobic pocket, with only the sulfate (substi-
tuted for the 3b-OH moiety) of the sterol exposed to solvent [20].
NPC1 also binds cholesterol and ﬂuorescent sterol analogs, as well
as oxysterols [19,21,22]. More recently, Kwon et al. reported the
crystal structure of the N-terminal loop of NPC1 and revealed that
this loop binds to cholesterol so that the 3b-OH group is buried
within the binding pocket and the iso-octyl side-chain is exposed
on the surface [23]. Since NPC1 and NPC2 appear to bind choles-
terol in opposite orientations, a model for the functions of the
two NPC proteins was proposed. In this model, unesteriﬁed cho-
lesterol in the interior of the LE/L is initially bound by NPC2
which subsequently transfers the cholesterol to the N-terminal
cholesterol-binding domain of NPC1 in the limiting membrane
of the LE/L (Fig. 1) [23]. This model predicts that NPC1 inserts
the iso-octyl side-chain of cholesterol into the lysosomal outer
membrane, although this feature remains to be conﬁrmed [23].
In support of this model, NPC2 greatly accelerates the bi-direc-
tional transfer of cholesterol from NPC1 to liposome acceptors,
particularly those containing the LE/L-speciﬁc phospholipid,
bis(monoacylglycero)phosphate [24]. The role that the sterol-
sensing domain of NPC1 plays in this process remains unclear
since mutations in this domain prevent the binding of a photo-
activatable analog of cholesterol to NPC1 in intact cells [25].
However, direct binding of this cholesterol analog to the sterol-
sensing domain was not demonstrated [25], leaving open the
possibility that this domain modulates cholesterol binding to
the N-terminal loop of NPC1. An alternative model that has been
proposed, and not yet ruled out, for the sequential action of NPC1
and NPC2 is that NPC1 transfers cholesterol to NPC2. No direct
interaction between the NPC1 and NPC2 proteins has been
detected.Other experiments, in which NPC1 was expressed in Escherichia
coli, indicated that NPC1 might be a fatty acid transporter [26]. In
these studies, NPC1 was able to transport oleic acid, but not choles-
terol or CE, across the E. coli membrane [26]. Nevertheless, subse-
quent work showed that the ﬂux of fatty acids through the
NPC1-deﬁcient LE/L is normal, suggesting that fatty acid export from
the LE/L does not require NPC1 inmammalian cells [27]. The ﬁnding
thatNPC1 that is expressed in E. coli cannotmediate the transbilayer
movement of cholesterol might indicate that NPC1 requires the
presence of functional NPC2 in order to transport cholesterol.
3. Abnormal lipid trafﬁcking in NPC-deﬁcient cells
The mechanisms responsible for the various pathways of inter-
organelle trafﬁcking of cholesterol within cells are largely unde-
ﬁned. The endocytic uptake of LDLs, and the subsequent hydrolysis
of CE, are normal in NPC1-deﬁcient cells [5]. However, the export of
cholesterol and other lipids from the LE/L is defective. Conse-
quently, normal amounts of cholesterol fail to reach the plasma
membrane and the ER for regulation of cholesterol homeostasis
[5,6]. Since cholesterol trafﬁcking to the ER is impaired in NPC-deﬁ-
cient cells, the cells sense a lack of cholesterol. Thus, cholesterol
synthesis and LDL-receptor expression are increased despite abnor-
mally elevated cholesterol levels in the LE/L [6]. The mechanism by
which cholesterol reaches the ER from the LE/L remains to be de-
ﬁned. Recent ﬁndings suggest that cholesterol is ﬁrst trafﬁcked
from the LE/L to the trans-Golgi network prior to reaching the ER
in a process that is dependent upon a SNARE complex, although
other possibilities exist [28]. Endogenously-synthesized cholesterol
can also accumulate within the LE/L, albeit much more slowly than
does LDL-derived cholesterol [29]. Unlike LDL-derived cholesterol,
the transport of endogenously-synthesized cholesterol to the plas-
mamembrane is not impaired in NPC1-deﬁcient ﬁbroblasts [29,30].
Presumably through formation of endocytic vesicles and mem-
brane recycling, this source of cholesterol can, however, also be-
come trapped in the LE/L. Furthermore, cholesterol that is taken
up through bulk-phase endocytosis also enters the LE/L and, as a
consequence, becomes trapped within the LE/L compartment of
NPC1-deﬁcient cells [31]. Interestingly, the intracellular transport
of cholesterol derived from high density lipoproteins appears to
be unaffected by NPC1 deﬁciency, suggesting that cholesterol de-
rived from these lipoproteins is processed in the cell through a
pathway different from that used by LDL-cholesterol [32].
In addition to cholesterol, a variety of other lipids, including
sphingomyelin, sphingosine, bis(monoacylglycero)phosphate, and
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GM2 and GM3) accumulate in the LE/L of NPC-deﬁcient cells (re-
viewed in [33]). There has been, and still is, debate over which lipid
is the ﬁrst to accumulate in NPC-deﬁcient cells, and which lipids
are responsible for the cellular dysfunction underlying NPC dis-
ease. Although the majority of data implicate cholesterol accumu-
lation as the primary defect, there is some evidence that points to
other lipids. For example, in a drug (U18666A)-induced model of
NPC disease the accumulation of sphingosine in the LE/L appar-
ently preceded both calcium depletion of these organelles and cho-
lesterol accumulation [34]. Moreover, calcium stores in the acidic
compartment of NPC1-deﬁcient cells were reduced, and the chela-
tion of calcium in the lumen of the endocytic pathway of wild-type
cells caused an NPC disease-like phenotype [34]. It should be
noted, however, that although U18666A induces cholesterol accu-
mulation in the LE/L, this compound does not precisely mimic NPC
deﬁciency and has additional effects on cholesterol homeostasis,
including inhibition of cholesterol synthesis [35,36]. It would be
interesting to determine if sphingosine accumulation is also the
initial event that causes lipid accumulation in the LE/L of NPC1-
deﬁcient cells.
Several studies indicate that GSL accumulation in the LE/L is not
the causative event in NPC disease. For example, NPC1-deﬁcient
mice that also have disrupted Galgt1 and Siat9 genes, and are un-
able to synthesize GM2/GD2 or GM3 complex gangliosides, accu-
mulate the same amount of cholesterol in LE/L in the brain and
other tissues as do NPC1-deﬁcient mice [37,38]. Moreover, rather
than extending the life of NPC1-deﬁcient mice, deletion of these
genes shortened the life-span, most likely because GSLs are impor-
tant for central nervous system (CNS) health and function [37,38].
Similarly, when mice lacking N-acetylgalactosamine transferase
(unable to synthesize GM2 and complex gangliosides) were
crossed with NPC1-deﬁcient mice, the absence of GM2 did not in-
crease the life-span of the NPC1-deﬁcient mice [39]. Thus, elimina-
tion of the GSL storage did not prevent development of the NPC
disease phenotype. On the other hand, in another study, elimina-
tion of the GSL biosynthetic enzyme N-acetylgalactosamine
transferase in NPC1-deﬁcient mice reduced ﬁlipin staining of cho-
lesterol in some, but not all, types of neurons in the brain, although
cholesterol content was not measured directly [40].
The idea that cholesterol is the initial lipid that accumulates in
NPC deﬁciency is strongly supported by the observation that both
NPC1 and NPC2 bind cholesterol [20,23], while this evidence is
lacking for other lipids such as GSLs. Currently, the majority of
experimental evidence supports a model in which mutation of
either NPC1 or NPC2 initially leads to cholesterol accumulation
in the LE/L, which in turn causes sequestration of a variety of other
lipids. Cholesterol accumulation in the LE/L also causes mis-traf-
ﬁcking of GSLs [41] and GSL accumulation can cause cholesterol
entrapment in the LE/L [42]. Cholesterol storage in the LE/L is in-
creased in several sphingolipid storage disorders, and depletion
of cholesterol from sphingolipid storage disease cells restored the
normal trafﬁcking of a ﬂuorescent GSL analog (BODIPY-lactosylcer-
amide) from the LE/L to the Golgi apparatus [41]. Moreover, when
wild-type cells were overloaded with cholesterol, the trafﬁcking of
BODIPY-lactosylceramide to the LE/L increased [41]. The afﬁnity of
cholesterol for GSLs is indicated by their association in detergent-
resistant domains of cell membranes. Thus, in NPC disease, not
only is it possible that the initial sequestration of cholesterol leads
to the accumulation of GSLs, but these GSLs might subsequently in-
duce the accumulation of even more cholesterol. We speculate that
this cyclic buildup of lipids within the LE/L might explain why
treatments that focus on reduction of GSL storage can provide a
therapeutic beneﬁt in NPC1-deﬁcient models [43]. Devlin et al.
provide compelling evidence in support of this theory, by demon-
strating that although impaired cholesterol trafﬁcking is mostlikely the primary defect in NPC1-deﬁcient cells, correction of a
secondary defect can substantially improve lipid and protein
trafﬁcking [44].
Another lipid that accumulates in the LE/L of NPC1-deﬁcient
cells is sphingomyelin. In response to the abnormal cholesterol
accumulation in membranes of the LE/L in NPC1-deﬁcient ﬁbro-
blasts, the activity of acid sphingomyelinase was reduced although
the amount of this enzyme was normal [44]. When normal levels
of acid sphingomyelinase activity were restored in the NPC1-deﬁ-
cient ﬁbroblasts, either through cDNA transfection or enzyme
replacement, a dose-dependent reduction in lysosomal cholesterol
content occurred and the abnormal recycling of the transferrin
receptor was partially corrected [44]. Even when normal sphingo-
myelinase activity was restored, the intensity of ﬁlipin staining re-
mained 25–30% higher than normal, most likely due to the primary
cholesterol trafﬁcking defect [44]. The same logic might explain
the partial success of miglustat treatment of children with NPC dis-
ease [45,46]. Miglustat is a small iminosugar that reversibly inhib-
its the ﬁrst step of GSL synthesis (glucosylceramide synthase),
improves the clinical symptoms, and increases the life-span of
NPC1-deﬁcient mice and cats [43]. This ‘‘substrate reduction ther-
apy” is a potentially useful treatment for NPC disease since the
residual activity of glucosylceramide synthase would likely pro-
duce sufﬁcient GSLs for functioning of the CNS.
There is evidence that cholesterol accumulation in the LE/L can
impair vesicular trafﬁcking pathways. Vesicles of the endocytic
pathway are transported along the cytoskeleton, a process that is
regulated by Rab GTPases (reviewed in [47]). Over-expression of
Rab7, which is involved in vesicle trafﬁcking from the early endo-
somes to LE, or over-expression of Rab9, which is involved in LE to
Golgi trafﬁcking, corrected the lipid trafﬁcking defects in NPC1-
deﬁcient ﬁbroblasts [48]. Likewise, over-expression of Rab4 (which
is involved in endocytic recycling to the plasma membrane) in
NPC1-deﬁcient cells also decreased cholesterol accumulation, and
restored normal trafﬁcking of BODIPY-lactosylceramide to the Gol-
gi apparatus [49]. Although Rab4 protein levels are elevated in
NPC1-deﬁcient cells, the sequestration of cholesterol in the LE/L
prevents the extraction of Rab4 from the endosomal membrane,
a key step required for Rab4 function [49]. As a consequence, the
Rab4-mediated recycling of lipids and proteins is impaired [49].
Modulation of pathways that involve Rab4, Rab7 or Rab9 was sug-
gested as a method of overcoming the trafﬁcking defects in NPC-
deﬁcient cells. Along these lines, over-expression of Rab9 in
NPC1-deﬁcient mice increased life-span and reduced ganglioside
storage in the brain [50]. Over-expression of Arf6 (which is in-
volved in regulation of early endosomal membrane internalization
and recycling) also reduced lipid accumulation in NPC1-deﬁcient
cells [51]. Furthermore, Goldman and Krise have demonstrated
that fusion/ﬁssion events between the LE and lysosomes are se-
verely impaired in NPC1- and NPC2-deﬁcient cells [52]. Intrigu-
ingly, it appears that NPC1 and NPC2 might be involved in
different aspects of this process, so that NPC1 is important for
the retrograde fusion of LE and lysosomes, while NPC2 plays a role
in ﬁssion events that might be important for re-formation of lyso-
somes [52]. Retrograde fusion of lysosomes with LE is thought to
be important for egress of membrane-impermeable cargo out of
the cell, and impairment of this pathway might cause a build-up
of toxic metabolites in the LE/L [52]. Indeed, the release of mole-
cules such as dextran and sucrose from NPC1-deﬁcient cells is im-
paired [12,52,53]. Thus, lipid accumulation within the LE/L can
severely reduce the trafﬁcking of lipids and other molecules
through the endocytic pathway.
Mitochondria are crucial for providing cells with energy in the
form of ATP, and also play a central role in apoptosis. Due to these
important functions, mitochondrial dysfunction has been impli-
cated in cell death in a variety of neurodegenerative disorders.
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pear to be impaired by NPC1 deﬁciency [54]. Indeed, the choles-
terol content of mitochondria in brains, neurons and hepatocytes
from NPC1-deﬁcient mice is increased [54–57], probably due to
the increased amounts of unesteriﬁed cholesterol in the LE/L that
are available for import into mitochondria. Interestingly, RNA
silencing of the endosomal protein MLN64 decreased the choles-
terol content of mitochondria, both in the absence and presence
of NPC1 indicating that MLN64 can mediate the transport of endo-
somal cholesterol into mitochondria independent of NPC1 [54].
Since cholesterol regulates membrane ﬂuidity, these changes in
mitochondrial cholesterol content might have a direct impact on
mitochondrial function and stability, as suggested in several stud-
ies. For example, mitochondrial membrane potential, the activity
of ATP synthase, and levels of ATP are all decreased in NPC1-deﬁ-
cient mouse brains and neurons [57]. Mitochondria from NPC1-
deﬁcient cells also have decreased levels of glutathione, which
serves as an important anti-oxidant defense. Consequently, these
cells have greater susceptibility to killing by tumor necrosis fac-
tor-a, as well as by oxidative stress induced by amyloid-b1-42
[55,56].4. Consequences of NPC deﬁciency in the liver and the brain
In individuals with NPC disease, cholesterol accumulates in al-
most all tissues of the body in amounts that are proportional to
the rate at which each tissue obtains cholesterol through the
LDL-receptor pathway [58]. The liver is responsible for the uptake
of 80% of LDL-cholesterol [58]. Although the rate of LDL-choles-
terol uptake by the liver is similar in wild-type and NPC1-deﬁcient
mice, the large ﬂux of cholesterol through the liver causes a mas-
sive accumulation of cholesterol within the LE/L of NPC1-deﬁcient
mice [58]. Consequently, markers of liver damage (alanine amino-
transferase and aspartate aminotransferase activities) are substan-
tially increased in NPC1-deﬁcient mice [59]. Moreover, 50% of
infants with NPC disease exhibit hepatomegaly which can lead to
liver failure and death [60]. Underscoring the unique role that
the liver plays in lipoprotein metabolism, the extent of cholesterol
accumulation in NPC1-deﬁcient mouse hepatocytes is much great-
er than in NPC1-deﬁcient ﬁbroblasts [61]; cholesterol levels in
hepatocytes from Npc1/ mice are 5- to 10-fold higher than in
Npc1+/+ mice [61]. Enigmatically, whereas in NPC1-deﬁcient ﬁbro-
blasts cholesterol esteriﬁcation is markedly attenuated, cholesterol
esteriﬁcation in NPC1-deﬁcient hepatocytes is increased [61]. In
addition, NPC1 deﬁciency in hepatocytes increases the expression
of ATP-binding cassette transporter A1 and the formation of high
density lipoproteins [62]. It is likely that the massive overload of
cholesterol in the LE/L of hepatocytes causes a leakage of excess
cholesterol from the LE/L so that cholesterol can be transported
to the ER where cholesterol homeostasis is regulated.
Defects in cholesterol metabolism in the brain have increasingly
been linked to neurodegenerative disorders such as Alzheimer dis-
ease and Huntington disease. Cholesterol metabolism in the brain
is unique, particularly since plasma lipoproteins are unable to cross
the blood–brain barrier. Consequently, essentially all of the choles-
terol in the brain must be synthesized endogenously [63]. The
brain contains 25% of the body’s cholesterol, but comprises only
5% of the body mass. The majority (70–80%) of cholesterol in the
brain is present in myelin; the rate of cholesterol synthesis in the
brain is highest during active myelination, and declines once mye-
lination is complete [64]. In the adult brain, cholesterol synthesis is
thought to occur primarily in astrocytes [65], which can supply
cholesterol to neurons in the form of apolipoprotein E-containing
lipoproteins (reviewed in [66]). Excess cholesterol in the brain is
excreted in the form of 24-hydroxycholesterol which is able tocross the blood–brain barrier and enter the circulation [67]. Sur-
prisingly, although cholesterol accumulates in tissues throughout
the body in NPC disease, the amount of cholesterol in the brain
does not increase, but even decreases, with age [58]. Several factors
may explain this apparent discrepancy. First, extensive demyelina-
tion occurs in the NPC1-deﬁcient brain, and since myelin is partic-
ularly rich in cholesterol, the demyelination would likely mask any
increase in cholesterol content of other cells in the brain [68]. Sec-
ond, the rate of cholesterol excretion from the brain is increased in
NPC1-deﬁcient mice [68]. However, as in other NPC1-deﬁcient
cells, cholesterol does accumulate in the LE/L of neurons of new-
born NPC1-deﬁcient mice [69] and in the brains of young NPC1-
deﬁcient mice, prior to extensive demyelination [68]. In addition,
increased cholesterol staining was observed in NPC1-deﬁcient
brain slices compared to wild-type brains [70]. However, these
studies did not determine if other lipids also accumulated in brains
of young NPC1-deﬁcient mice.
Since the blood–brain barrier isolates the brain from cholesterol
in the circulation, treatments that modulate cholesterol homeosta-
sis in other tissues will not necessarily translate into improvement
of neurological symptoms of diseases that involve defects in cho-
lesterol metabolism. Thus, when NPC1-deﬁcient mice were crossed
with LDL-receptor knockout mice the neuropathological features of
NPC disease did not improve [71]. The lack of a beneﬁcial effect of
cholesterol-lowering treatments in the brain might be due to con-
tributions of other lipoprotein receptors in the brain, or to the
accumulation of endogenously-synthesized cholesterol within
neurons. In support of the latter explanation, NPC1-deﬁcient
mouse sympathetic neurons [69], embryonic hippocampal neurons
[33], and cerebellar granule neurons (K.B. Peake and J.E. Vance,
unpublished observations) showed the typical punctate ﬁlipin
staining pattern of cholesterol sequestration in the LE/L, even in
neurons that had been isolated from newborn mice or cultured
for 20 days in the complete absence of lipoproteins. Pharmacolog-
ical attempts at lowering plasma cholesterol also failed to improve
the NPC phenotype [72], possibly because some cholesterol-lower-
ing drugs cannot cross the blood–brain barrier. On the other hand,
when cholesterol synthesis was blocked using a squalene synthase
inhibitor in young NPC1-deﬁcient mice prior to formation of the
blood–brain barrier, cholesterol accumulation in neurons was
attenuated, as was astrocyte activation [73]. Importantly, however,
blocking cholesterol synthesis at this early stage of mouse develop-
ment might have disrupted the myelination process, which could
negate any beneﬁcial effects of this treatment for NPC1 deﬁciency
[73]. When cholesterol homeostasis was altered using a liver X
receptor agonist, however, the life-span of NPC1-deﬁcient mice
was extended and the neurodegeneration was delayed [74]. While
the liver X receptor agonist did not reduce cholesterol concentra-
tion or synthesis in the brain, excretion of cholesterol from the
CNS was increased [74]. Thus, modulation of cholesterol metabo-
lism in NPC-deﬁcient brains might reduce the severity and pro-
gression of NPC disease. Nevertheless, the importance of
adequate levels of cholesterol for brain development and function,
along with the problem of overcoming the blood–brain barrier,
represent some of the many technical difﬁculties associated with
altering cholesterol metabolism in the CNS.
Neurodegeneration in NPC disease occurs in a progressive and
neuron-selective manner, and is particularly evident in Purkinje
cells of the cerebellum. In NPC1-deﬁcient mice, Purkinje cell death
is ﬁrst evident around 3 weeks after birth, with nearly all Purkinje
cells dying by 11 weeks [75,76]. Neuronal loss is also evident in
other brain regions including the substantia nigra, pons, regions
of the brainstem, thalamus, and prefrontal cortex [77–79]. NPC1
deﬁciency in the brain causes a variety of neuronal abnormalities
that could lead to neuronal dysfunction and/or death. The reason
for the selective neurodegeneration in NPC disease has yet to be
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the levels and activity of the lysosomal enzymes cathepsins B
and D are elevated to a greater extent in the cerebellum than in
the hippocampus which is relatively protected from neurodegener-
ation [80]. Furthermore, cytosolic levels of cathepsins and
apoptotic molecules are higher in the cerebellum than in the hip-
pocampus [80]. Experiments with chimeric mice, that contain both
Npc1+/+ and Npc1/ cells, showed that the death of NPC1-deﬁcient
Purkinje cells was not prevented by the presence of wild-type glia
[81]. Nor did NPC1-deﬁcient glia induce death of wild-type Pur-
kinje cells, suggesting that death of Purkinje cells is cell autono-
mous [81]. In support of these ﬁndings, Elrick et al. recently
generated mice that lacked NPC1 in only the Purkinje cells [82].
The same extent of Purkinje cell death occurred in these mice as
in NPC1 global null mice [82]. Interestingly, however, although
these mice showed progressive motor impairment, they did not ex-
hibit other typical manifestations of NPC disease such as weight
loss and early death [82]. These important studies demonstrate
that the premature death of NPC1-deﬁcient mice is not due (solely)
to the death of Purkinje cells.
The mechanism by which Purkinje cells, and other neurons,
degenerate in NPC disease remains unclear. Markers of autophagy
(beclin-1 and microtubule-associated protein 1 light chain 3-II)
were detected in brains of Npc1/ mice [83,84], and electron
microscopy revealed autophagic vesicles in Npc1/ Purkinje cells
[81]. Autophagy is the process through which cells degrade long-
lived proteins and organelles via lysosomes. During periods of star-
vation, autophagy is crucial for providing cells with energy through
digestion of non-essential cellular components. Signs of autophagy
have been detected in other neurodegenerative disorders including
Alzheimer disease, Parkinson disease and Huntington disease,
leading to speculation that excessive or impaired autophagy leads
to neuronal cell death. In NPC disease, the induction of autophagy
may serve as a mechanism for counteracting the abnormal accu-
mulation of lipids within the LE/L, or as a starvation response to
the sequestration of lipids in LE/L. Although it is possible that accu-
mulation of lipids within lysosomes impairs their ability to bind to
autophagosomes for degradation of engulfed material, degradation
of long-lived proteins was increased in NPC1-deﬁcient human
ﬁbroblasts, suggesting that the autophagy pathway was intact
[84]. It remains to be determined whether or not autophagy con-
tributes to neuronal death in NPC disease.
Apoptosis of neurons has also been observed in NPC disease.
TUNEL-positive staining of nuclei in the cerebral cortex and cere-
bellum was evident in NPC patients and NPC1-deﬁcient mice
[85]. Moreover, the level of mRNAs encoding tumor necrosis fac-
tor-a and players in the tumor necrosis factor-a death pathway
in the brain were higher in Npc1/ mice than in Npc1+/+ mice
[85]. The expression of other markers of apoptosis, including
mRNAs encoding caspases 1 and 3 [75], as well as activation of
the c-Abl/p73 pro-apoptotic pathway [86], was also increased in
the cerebellum of NPC1-deﬁcient mice. Treatment of Npc1/mice
with imatinib, an inhibitor of c-Abl, reduced Purkinje cell death,
improved neurological symptoms and modestly extended the
life-span [86].
In addition to neuronal death in NPC disease, other neuronal
functions are likely to be impaired by NPC deﬁciency. The transport
of cholesterol from cell bodies to distal axons of isolated neurons is
reduced by NPC1 deﬁciency [87]. Correspondingly, the cholesterol
content of cell bodies of Npc1/ neurons is increased whereas the
cholesterol content of distal axons is reduced in [69]. Moreover, the
NPC1 protein is present not only in the LE/L of cell bodies of sym-
pathetic neurons but also in recycling endosomes of pre-synaptic
nerve terminals [88]. This observation might explain the defects
in synaptic functions in NPC1-deﬁcient neurons [89,90]. NPC1-
deﬁcient neurons in humans, felines, and mice, show additionalabnormalities such as dendritic and axonal alterations that include
ectopic dendrites and axonal spheroids [91]. Furthermore, NPC dis-
ease exhibits some similarities to Alzheimer disease as neuroﬁbril-
lary tangles and hyperphosphorylation of tau are evident in both
Alzheimer patients and in NPC disease patients [92,93]. However,
neuroﬁbrillary tangles are absent in NPC1-deﬁcient mice despite
the hyperphosphorylation of tau [77,94].
Although much focus has been directed at neuronal death in
NPC disease, the brain also contains many glial cells which are cru-
cial for brain function. Astrocytes, the major glial cell type in the
CNS, play important roles in supporting neuronal functions, partic-
ularly at the synapse. As in other NPC1-deﬁcient cells, Npc1/
mouse astrocytes sequester cholesterol within LE/L [95], and
reactive astrocytes have been detected throughout the brains of
4-week-old Npc1/ mice, particularly in the cerebellum and thal-
amus [96]. The ﬁnding that NPC1 protein is localized predomi-
nantly in astrocytic processes in monkey brains suggests that
mutations in NPC1 might impair astrocyte function [97]. Surpris-
ingly, despite these astrocyte abnormalities, the quantity and com-
position of apolipoprotein E-containing lipoproteins secreted by
Npc1+/+ and Npc1/mouse astrocytes are similar, and the lipopro-
teins secreted by astrocytes of both Npc1 genotypes promote axon
growth to the same extent [95]. On the other hand, when Npc1+/+
neurons were cultured on Npc1/ astrocytes, neurite growth
was reduced compared to that of Npc1+/+ neurons cultured on
Npc1+/+ astrocytes [98]. In addition, the expression of neurosteroid
biosynthetic enzymes, and the secretion of the neurosteroid estra-
diol, were lower in Npc1/ astrocytes than in Npc1+/+ astrocytes
[98]. Estradiol levels were also lower in NPC1-deﬁcient mouse
brains, and administration of estradiol to Npc1/ mice alleviated
some of the symptoms of NPC disease [98]. These results imply
that impaired neurosteroid synthesis in NPC1-deﬁcient astrocytes
might contribute to neuronal death in NPC disease. In other exper-
iments, NPC1 was over-expressed in astrocytes of NPC1-deﬁcient
mice using the glial ﬁbrillary acidic protein promoter [99]. Neuro-
degeneration and the neuronal storage of cholesterol in the mice
were decreased and life-span was increased compared to those
parameters in the Npc1/ mice [99]. However, the expression of
NPC1 in astrocytes of Npc1/ mice did not prevent Purkinje cell
loss [99], suggesting that astrocyte dysfunction alone does not ac-
count for the extensive neuron loss in NPC disease.
Microglia are the resident immune cells of the CNS and play a
key role in maintaining brain health. In a healthy brain, microglia
exist in the ‘‘ramiﬁed” state for continuous monitoring of the
brain environment [100]. Perturbation of this environment can
activate microglia and lead to a variety of responses, depending
on the stimulus. For example, microglia can secrete anti-inﬂam-
matory cytokines, as well as pro-inﬂammatory cytokines and
potentially cytotoxic molecules that include glutamate and reac-
tive oxygen species (reviewed in [101]). Increasing evidence sug-
gests that chronic microglial activation or microglial dysfunction
contributes to neuronal death in various neurodegenerative dis-
orders including Alzheimer disease, Parkinson disease, and the
lysosomal storage disorder, Sandhoff disease. In 2-week-old
Npc1/ mice, microglia with an ‘‘active” morphology were
detected in brain regions such as the cerebellum, and the number
of these cells increased throughout the brain as the disease
progressed [96]. Moreover, the level of mRNA encoding the
pro-inﬂammatory cytokine, tumor necrosis factor-a, in the cere-
bellum was increased by NPC1 deﬁciency [75,85]. Primary
microglial cultures from NPC1-deﬁcient mice show a punctate
cholesterol staining pattern, as well as increased immunostaining
for tumor necrosis factor-a (K.B. Peake and J.E. Vance, unpub-
lished observations).
Although experiments in chimeric mice suggest that Purkinje
cell death is cell autonomous [81], these experiments did not
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Npc1+/+ Purkinje cells to killing by Npc1/microglia. It is also pos-
sible that microglia contribute to the death of neurons other than
Purkinje cells. Baudry et al. detected active microglia in Npc1/
mouse brains, prior to any signs of neurodegeneration, suggesting
that NPC1 deﬁciency in microglia might activate the microglia and,
consequently, cause neuronal death [96]. It is also possible that
neuronal damage and dysfunction that are not easily detected
experimentally can activate microglia, which in turn might exacer-
bate the neurodegeneration. Conversely, NPC1 deﬁciency in
microglia might impair normal microglial function and prevent
the microglia from rescuing or repairing damaged neurons. Thus,
more studies are required to determine if the microglial activation
that occurs in NPC1-deﬁcient brains contributes to, or is the result
of, the neuronal death.
Oligodendrocytes are the glial cells that form myelin sheaths
around axons in the brain and are, therefore, essential for proper
neuronal function. The NPC1-deﬁcient mouse brain exhibits
extensive demyelination, especially in the corpus callosum, where
myelin is essentially absent by 8 weeks of age [68,102]. Pre-myeli-
nating oligodendrocytes and oligodendrocyte progenitor cells are
abundant in Npc1/mouse brain regions that show hypomyelina-
tion, including the corpus callosum and cerebral cortex [103]. The
abundance of these precursor cells and the lack of mature oligo-
dendrocyte markers in hypomyelinated regions suggest that
NPC1 deﬁciency causes a defect in myelination [103]. This abnor-
mal myelination might be due to axonal damage, which occurs
early during development of the NPC1-deﬁcient mouse brain
[79]. On the other hand, inclusion bodies have been detected in
Npc1/ oligodendrocytes, suggesting that defects in myelination
might be due to oligodendrocyte dysfunction [104]. As is the case
for oligodendrocytes in the CNS, immortalized Schwann cells of
the peripheral nervous system showed punctate ﬁlipin staining
[105], and hypomyelination of peripheral nerves was observed in
70-day-old Npc1/ mice [106]. Furthermore, myelination in the
peripheral nervous system of Npc1/mice was impaired following
sciatic nerve crush injury [107]. In Npc1+/+ mice, thick myelin
sheaths surrounded the axons 4 weeks after the crush injury,
whereas NPC1-deﬁcient mice had thinner sheaths [107], although
10 weeks after the injury, the extent of myelination in the Npc1/
mice was comparable to that in Npc1+/+ mice [108]. These altera-
tions in myelination might contribute to the neuronal dysfunction
and degeneration characteristic of NPC disease.
Thus, the implications of NPC1 deﬁciency in the nervous system
are very complex and incompletely understood. Experimental evi-
dence indicates that the neurological phenotype of NPC disease,
and the extensive death of neurons, likely arise from an interplay
among the different cell types in the brain: neurons, astrocytes,
microglia and oligodendrocytes.5. Therapies for NPC disease
No treatments are currently available for NPC disease other
than those used to alleviate the symptoms caused by disease pro-
gression. Recently, however, miglustat was approved in Europe for
the treatment of adult and pediatric patients with NPC disease.
Miglustat had initially been approved for treatment of patients
with Gaucher disease, a lysosomal GSL storage disorder [109].
Administration of miglustat to animal models of NPC disease,
including mice and cats, reduced ganglioside accumulation in the
brain, delayed neurological symptoms, and increased life-span
[43]. Data from initial clinical trials suggest that long-term treat-
ment of NPC patients with miglustat is well tolerated in adult
and juvenile patients, and can stabilize some of the neurological
symptoms [45,46].Another therapeutic strategy that was proposed for NPC disease
was the administration of neurosteroids [110]. Cholesterol is a pre-
cursor of the neurosteroids (i.e. steroids that are synthesized in the
brain) that are important for neuron growth and development. In
brains of NPC1-deﬁcient mice, levels of pregnenolone and the neu-
rosteroid allopregnanolone (ALLO), as well as the activities of the
enzymes involved in ALLO synthesis, are lower than in wild-type
mice [110]. Remarkably, a single injection of ALLO in 7-day-old
NPC1-deﬁcient mice delayed the onset of neurological symptoms
and increased life-span. Purkinje cell survival was also increased,
while levels of GM1 and GM2 gangliosides were reduced [110].
Other studies reported that ALLO reduced microglial activation
and astrocyte proliferation, and increased myelination [111,112].
At the cellular level, ALLO decreased the amount of ﬁlipin-labeled
cholesterol, as well as markers of autophagy and the levels of lyso-
somal enzymes [112]. Although a GABAA receptor antagonist
blocked the beneﬁcial effect of ALLO on Purkinje cell survival, a ste-
reoisomer of ALLO, ent-ALLO (which is not a GABAA receptor ago-
nist) promoted neuronal survival to the same extent as ALLO
[110,113]. Langmade et al. proposed that induction of pregnane
X receptor-dependent gene expression by treatment of NPC1-deﬁ-
cient mice with ALLO or ent-ALLO mediated the beneﬁcial effects of
the neurosteroid [113]. However, it is difﬁcult to rationalize why
ALLO would improve the neurodegenerative phenotype through
the pregnane X receptor since expression of this receptor was
undetectable in the brain [74].
Recently, the reported beneﬁcial effects of ALLO have come un-
der intense scrutiny due to effects caused by the vehicle, cyclodex-
trin (CD), that was used in the experiments with ALLO described
above. CD is a cyclic oligosaccharide capable of sequestering lipids,
especially cholesterol, within its hydrophobic core [114]. Interest-
ingly, recent work of Liu et al. found that treatment of NPC1-deﬁ-
cient mice with CD delayed the neurodegeneration and prolonged
the life of the mice independent of ALLO administration [37]. A sin-
gle dose of CD given to 7-day-old NPC1-deﬁcient mice reduced the
accumulation of unesteriﬁed cholesterol, increased the amount of
CE, and decreased cholesterol synthesis in the liver, spleen and,
to a lesser extent, the brain [115]. In addition, chronic administra-
tion of CD to mice delayed clinical onset of the disease and in-
creased life-span of both NPC1- and NPC2-deﬁcient mice [116].
Filipin staining and immunohistochemical analysis revealed that
chronic CD treatment of mice reduced the amount of unesteriﬁed
cholesterol, as well as the gangliosides GM1 and GM2, in NPC1-
and NPC2-deﬁcient mouse brains [116]. Although the mechanism
underlying this striking effect of CD has not been completely eluci-
dated, the current model is that CD enters the endocytic pathway
through bulk-phase endocytosis and releases cholesterol and other
lipids that are trapped in the LE/L so that the cholesterol can reach
the ER [115]. In support of this model, in NPC1-deﬁcient mouse
brains and livers the levels of the mRNAs encoding sterol-response
element-binding protein-2 and its target genes were decreased by
CD administration, whereas the mRNAs encoding liver X receptor
target genes were increased [115]. In addition, when NPC1-deﬁ-
cient cultured mouse ﬁbroblasts were treated with CD in vitro,
ACAT-mediated cholesterol esteriﬁcation was increased, indicating
that cholesterol had been released from the LE/L and transported to
the ER [117]. If, on the other hand, cholesterol had been stripped
from the plasma membrane by CD, one would have expected that
cholesterol synthesis would have increased as compensation for
the loss of cholesterol. Thus, the ﬁnding that cholesterol synthesis
was decreased, not increased, by CD treatment suggests that the
primary effect of CD is mobilization of cholesterol from the LE/L
rather than the plasma membrane [115]. The idea that CD can
extract cholesterol from the LE/L is supported by recent work
indicating that dextran-conjugated CD localizes to intracellular
ﬁlipin-stained organelles and reduces cholesterol accumulation
Fig. 2. CD treatment reduces the intracellular sequestration of cholesterol staining
in Npc1/ neurons. Cerebellar granule neurons, isolated from 7- to 8-day-old
Npc1/ mice, were cultured for 7 days in the absence of serum, then treated for
24 h with vehicle (a), or 0.1 mM (2-hydroxypropyl)-b-cyclodextrin (CD) (b), prior to
being ﬁxed and stained with ﬁlipin and examined by ﬂuorescence microscopy.
Images are representative of three independent experiments.
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either astrocytes or cerebellar granule neurons from Npc1/ mice
were cultured in vitro with low concentrations of CD, the punctate
ﬁlipin staining was reduced (Fig. 2) and cholesterol synthesis was
decreased. In contrast, higher concentrations of CD, which presum-
ably would have extracted signiﬁcant amounts of cholesterol from
the plasma membrane, increased cholesterol synthesis in Npc1/
neurons (K.B. Peake and J.E. Vance, unpublished observations).
The precise mechanism by which CD mediates these effects is un-
known. Other experiments by Davidson et al. suggest that the
administration of ALLO alone to NPC1-deﬁcient mice, without CD
has no beneﬁcial effects, whereas the administration of CD with
ALLO is more beneﬁcial than CD alone [116], although these con-
clusions remain controversial. Thus, further investigations are
needed to clarify the role of ALLO in the treatment of NPC disease.
Although the recent development of potential therapies for NPC
disease has shown promising advances, one of the major obstacles
that remains is the efﬁcient and rapid diagnosis of NPC disease
which would allow treatment to be initiated as early as possible.
NPC disease has a signiﬁcant delay in diagnosis after onset of
symptoms, with one recent study ﬁnding that the average delay
in diagnosis was 4.3 years with a range of 3 months to 19 years
[119]. Most of the experiments in which therapeutic compounds
were administered to animals were performed prior to the onset
of neurological symptoms. While these treatments yielded encour-
aging results, when the same compounds were administered at la-
ter stages of disease progression, the results were not as positive.
For example, signiﬁcant improvements occurred when CD was
administered to 7-day-old mice prior to the onset of overt neuro-
degenerative symptoms. However, when a single dose of CD was
given to 49-day-old mice, the amount of cholesterol that accumu-
lated in tissues throughout the body was reduced but life-span was
not extended [120]. The latter observation might be explained by
the fact that CD can enter the brain from the circulation in 7-
day-old mice, prior to formation of the blood–brain barrier,
whereas access of CD to the brain might be impeded in adult mice
with an intact blood–brain barrier. In addition, beneﬁcial effects of
CD might occur only if CD were chronically administered, particu-
larly at later stages of disease progression. However, it appears that
there might be a critical therapeutic window, after which irrevers-
ible damage occurs, so that any therapy for the disease will only
prevent further progression. Thus, better screening processes and
increased awareness of NPC disease are needed, as early treatment
will likely have the greatest beneﬁt. Nonetheless, recent therapeu-
tic advances such as treatments with miglustat and CD provide op-
tions that show promise in slowing the progression of NPC disease.
Due to the complex nature of NPC disease, a combination ofvarious treatments will probably have the greatest therapeutic
effect.
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